Patent · US Active

Humanized antibodies against CXCR3

US8435522B2 · kind B2 · utility

0Cited by

0References

25Claims

0Family size

Assignee

TEV A Biopharmaceuticals USA, Inc. · US

Inventors

Rodger Smith · Jefferson, US
Palanisamy Kanakaraj · Germantown, US
Viktor Roschke · Rockville, US

Key dates

Filing date	Jan 29, 2008
Grant date	May 7, 2013
Priority date	—
Expiry date	Nov 29, 2029

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed are humanized antibodies that bind specifically to the receptor CXCR3. The humanized antibodies may be antagonists and may be used to treat or diagnose conditions associated with CXCR3 function.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.